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Abstract
Combinatorial libraries of artificial zinc-finger transcription factors (ZF-TFs) provide a robust tool for inducing and
understanding various functional components of the cancer phenotype. Herein, we utilized combinatorial ZF-TF library
technology to better understand how breast cancer cells acquire resistance to fulvestrant, a clinically important anti-
endocrine therapeutic agent. From a diverse collection of nearly 400,000 different ZF-TFs, we isolated six ZF-TF library
members capable of inducing stable, long-term anti-endocrine drug-resistance in two independent estrogen receptor-
positive breast cancer cell lines. Comparative gene expression profile analysis of the six different ZF-TF-transduced breast
cancer cell lines revealed five distinct clusters of differentially expressed genes. One cluster was shared among all 6 ZF-TF-
transduced cell lines and therefore constituted a common fulvestrant-resistant gene expression signature. Pathway
enrichment-analysis of this common fulvestrant resistant signature also revealed significant overlap with gene sets
associated with an estrogen receptor-negative-like state and with gene sets associated with drug resistance to different
classes of breast cancer anti-endocrine therapeutic agents. Enrichment-analysis of the four remaining unique gene clusters
revealed overlap with myb-regulated genes. Finally, we also demonstrated that the common fulvestrant-resistant signature
is associated with poor prognosis by interrogating five independent, publicly available human breast cancer gene
expression datasets. Our results demonstrate that artificial ZF-TF libraries can be used successfully to induce stable drug-
resistance in human cancer cell lines and to identify a gene expression signature that is associated with a clinically relevant
drug-resistance phenotype.
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Introduction
Combinatorial libraries of artificial zinc-finger transcription
f a c t o r s( Z F - T F s )p r o v i d eap o w e r f u lt o o lf o ri n d u c i n ga n d
understanding important cellular phenotypes [1,2]. Zinc fingers
are compact ,30 amino acid domains that can be engineered to
bind various three bp DNA ‘‘subsites’’ [3,4]. By ‘‘mixing and
matching’’ collections of individual zinc fingers with various pre-
selected DNA-binding specificities, large collections (or ‘‘librar-
ies’’) of multi-finger arrays, each predicted to bind a different
spectrum of target DNA sequences, can be easily assembled
[1,2]. These multi-finger arrays can in turn be fused to
transcriptional regulatory domains to create libraries of artificial
ZF-TFs capable of activating or repressing expression of specific
genes. Previous studies have shown that such libraries can be
screened to identify specific ZF-TFs capable of inducing
phenotypes of interest in bacteria, yeast, and mammalian cells
[1,2,5,6,7,8,9,10,11,12].
We sought to use combinatorial ZF-TF library technology to
induce resistance to fulvestrant, a clinically important anti-
endocrine therapeutic agent. In the United States, approximately
70% of all breast cancer patients are diagnosed with estrogen
receptor (ER)-positive breast cancer and anti-endocrine drug
resistance, whether inherent or acquired, occurs in 30% of all ER-
positive breast cancer patients [13,14]. We reasoned that
pertubation of molecular gene expression patterns in cells could
lead to anti-endocrine resistance and that identification of these
gene expression alterations could potentially lead to identification
of novel and more effective therapeutic markers and targets.
In this report, we describe the construction of a large ,400,000
member ZF-TF library and the identification of six library
members capable of inducing stable, long-term anti-endocrine
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21112drug-resistance in breast cancer cells. High-density microarray
analysis of differential gene expression patterns induced by these
six artificial transcriptional factors revealed a common set of 72
target genes (a common fulvestrant-resistant gene expression
signature) predicted to be involved in cellular pathways influenced
by different classes of anti-endocrine agents. Highlighting the
potential translational relevance of this approach, interrogation of
the common fulvestrant-resistant gene expression signature in
publicly available gene data sets demonstrated a positive
association with poor prognosis in breast cancer patients. Taken
together, our results demonstrate that artificial zinc finger
transcription libraries can be used to induce stable drug-resistance
in human cancer cell lines and to identify clinically relevant genes
associated with the resistance phenotype.
Results
Construction of a combinatorial ZF-TF Library
Individual zinc finger domains typically bind to approximately
3 bp of DNA [4,15]. These domains can be linked together into
longer arrays of three or more fingers capable of recognizing
longer DNA sequences (Figure 1A) [16,17,18]. Previous reports
have described collections of various naturally occurring and
engineered zinc finger domains with specificities for various three
bp DNA sites. Several groups have created artificial ZF-TF
libraries by randomly assembling combinations of individual zinc-
finger domains with pre-characterized DNA-binding specificities
into libraries of either three, four, or six-finger proteins [1,2]. Each
member of such a library has the potential to alter the expression
of a spectrum of different genes in a cell, particularly if fused to a
transcriptional regulatory domain (e.g.—an activation or a
repression domain) [1,2] Using 25 different zinc-finger domains
(Table 1), we used a ‘‘mix and match’’ approach to create a
combinatorial ZF-TF library consisting of as many as 390,625
(25
4) different four-finger proteins each fused to a NF -KB p65
activation domain encoded in a retroviral vector that can confer
puromycin-resistance (Figure 1B).
Identification of ZF-TFs that induced Fulvestrant-
Resistance in MCF7 Cells
We used the approach outlined in Figure 1C to identify
members of the ZF-TF library that were capable of inducing
resistance to fulvestrant in breast cancer cells. For these
experiments, we transduced MCF7-R73 cells, a monoclonal
MCF7 subline that is highly sensitive to fulvestrant-induced
cytocidal activity [19], with the ZF-TF activator library or with
control retrovirus encoding only the NF-KB p65 activation
domain. Both populations of cells were initially enriched for
transduced cells by selecting for growth in puromycin and then for
fulvestrant-resistant cells by selecting in the presence of 100 nM
fulvestrant. After six weeks of continuous treatment with
fulvestrant, hundreds of drug-resistant colonies emerged from
the population of cells infected with the ZF-TF activator library
(Figure 1D). By contrast, as expected, the control MCF7cells
transduced by the control NF-KB p65-only retrovirus underwent
massive cell death and therefore did not form drug-resistant
colonies.
DNA encoding ZF-TFs was rescued by PCR from the genomic
DNA of pooled fulvestrant-resistant cells. The sequences of the
individual ZF-TFs were determined and 46 unique ZF-TF clones
identified. These 46 unique ZF-TFs were re-cloned into the
retroviral vector and converted into clonal virus stocks that were
used to transduce MCF7-R73 cells. These 46 retrovirally
transduced cell populations were then challenged with fulvestrant
(Figure 1C). Compared with the control MCF7-R73 cells
transduced with the NF-KB p65-only retrovirus (hereafter referred
to as MCF-238 cells), the MCF7-R73 cells transduced with six of
the 46 unique ZF-TFs demonstrated survival and growth in the
presence of 100 nM fulvestrant (Figures 2A and B). The sequences
of the six ZF-TF arrays conferring fulvestrant resistance are
presented in Table 2. To test whether these six ZF-TFs could
induce fulvestrant-resistant in cells other than MCF7-R73, T47D
breast cancer cells, a second fulvestrant-sensitive ER+ human
breast cancer line, were individually transduced with each of the
six different ZF-TFs and challenged with fulvestrant. Similar to
what was observed with MCF7-R73 cells, the six ZF-TFs
conferred resistance to fulvestrant-induced growth inhibition in
T47D cells (Figure 2C). Consistent with its reported mechanism of
action, fulvestrant suppressed ER2alpha expression in all ZF-TF-
induced resistant sublines and the sensitive MCF7-238 control
subline (Figure S1). Given that fulvestrant suppressed ER2 alpha
expression to a level equal to or greater than that observed in the
control cells, it is unlikely that drug resistance was caused by
enhanced drug metabolism or active drug exclusion. In order to
assess the latter possibility, we performed drug sensitivity testing as
previously described [20] to 24 chemotherapeutic agents and
investigational compounds (Table S1) in three different ZF-TF-
transduced fulvestrant-resistant cell lines. Comparison of the
control MCF7-R73 cells to the three ZF-TF fulvestrant resistant
cell lines revealed no significant difference in the pattern of drug
resistance and sensitivity suggesting that the ZF-TFs are not
inducing a multi-drug resistance phenotype (Figure S2).
To rule out that selection in fulvestrant was required for the
phenotype of ZF-induced drug resistance, we transduced MCF7-
R73 cells with the six ZF-TFs, subjected the cells to 3 weeks of
puromycin selection, and then challenged the transduced cells with
100 nM fulvestrant. Despite the absence of selection in fulvestrant,
all six ZF-TFs again conferred fulvestrant resistance (Figure 2D).
To determine if the NF-KB p65 activation domain is required for
ZF-TF-induced fulvestrant resistance, MCF7-R73 cells were
transduced with retrovirus expressing only the ZF-TFs (i.e.-
without a fused p65 activation domain) and challenged with
fulvestrant. These transduced MCF7-R73 cells were all found to
be sensitive to fulvestrant-induced cell growth inhibition and cell
death (Figure 2E), demonstrating that the NF-KB p65 activation
domain is required for ZF-TF-induced fulvestrant resistance.
Gene Expression Profiling
To determine the transcriptional alterations associated with ZF-
TF-induced fulvestrant resistance, we performed comparative
gene expression profiling of each of the six ZF-TF-transduced
MCF7 cell lines relative to the control MCF7-238 cells.
Fulvestrant exposure induces massive cell death in our control
MCF7-238 cells. Thus, in order to avoid the confounding effects of
cell death-associated gene expression alterations, we performed
our expression profiling analysis using MCF7-238 cells and ZF-
TF-induced fulvestrant resistant cells grown in the absence of
fulvestrant for 3 days. Cluster analysis of the differential expression
profiles of the ZF-TF-infected cells and the control cells identified
a shared cluster of genes up-regulated by ZF-TF 7, 19 and 70
(Figure 3A, purple rectangle, henceforth gene cluster 1), and
distinctive gene expression patterns induced by ZF-TF 64, 83 and
115 (Figure 3A, black rectangles, henceforth gene clusters 2, 3 and
4, respectively). A gene cluster consistently up-regulated in all six
fulvestrant resistant cell lines was not identified. However, a 72-
gene cluster was consistently down-regulated in all six fulvestrant
resistant cell lines (Figure 3A, green rectangle, henceforth gene
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resistant gene expression signature (Table S2).
To gain additional insights into the biological processes in which
these various differentially expressed genes are involved, we
performed hypergeometric gene set enrichment analysis (GSEA) of
the different ZF-TF-induced gene set clusters using the BROAD
Institute MSigDB gene set database augmented with ESR1,
ERBB2 and proliferation coexpression modules [21,22], MYB
regulated genes [23] and a signature of long-term estrogen
deprivation [24]. Two prominent findings emerged from this
analysis. First, the shared cluster of up-regulated gene expression
induced by ZF-TF 7, 19 and 70 (cluster 1) and the unique gene
clusters (cluster 2, 3 and 4) induced by ZF-TF 64, 83 and 115,
respectively, show significant overlap with myb-regulated genes
(Tables S3, S4, S5, S6). Second, and most notable, gene set
enrichment analysis of the common fulvestrant resistant gene
expression signature (cluster 5) revealed significant overlap with
gene sets associated with estrogen receptor negative human breast
cancers, with estradiol responsiveness, and with anti-endocrine
drug resistance to tamoxifen [25,26,27], fulvestrant [26] and
aromatase inhibitors [25] in multiple breast cancer cell lines
including long-term estrogen-deprived (LTED) cells [24]. (Table
S7). Thus, the common fulvestrant-resistance gene expression
signature induced by six different ZF-TFs represents an estrogen
receptor-negative-like transcriptional state that is associated with
an anti-endocrine resistance phenotype.
We next sought to compare the patterns of gene expression
observed in our ZF-TF-induced fulvestrant resistant MCF7 cells
Table 1. Twenty-five individual zinc fingers used to construct the combinatorial ZF-TF library.
Zinc Finger Name Expected Target Subsite (59 to 39) Zinc Finger Amino Acid Sequence Reference
LZF01 GAV YKCKQCGKAFGCPSNLRRHGRTH Bae et al., 2003 [19]
LZF02 GAW YRCKYCDRSFSISSNLQRHVRNIH Bae et al., 2003 [19]
LZF03 GGA YKCGQCGKFYSQVSHLTRHQKIH Bae et al., 2003 [19]
LZF04 HGA YKCEECGKAFRQSSHLTTHKIIH Bae et al., 2003 [19]
LZF05 GAA FECKDCGKAFIQKSNLIRHQRTH Bae et al., 2003 [19]
LZF06 NAA YVCSKCGKAFTQSSNLTVHQKIH Bae et al., 2003 [19]
LZF07 GYA YKCPDCGKSFSQSSSLIRHQRTH Bae et al., 2003 [19]
LZF08 HGA YECHDCGKSFRQSTHLTQHRRIH Bae et al., 2003 [19]
LZF09 GHG YVCDVEGCTWKFARSDELNRHKKRH Bae et al., 2003 [19]
LZF10 NGG FQCKTCQRKFSRSDHLKTHTRTH Bae et al., 2003 [19]
LZF11 GGG YKCMECGKAFNRRSHLTRHQRIH Bae et al., 2003 [19]
LZF12 GAG YICRKCGRGFSRKSNLIRHQRTH Bae et al., 2003 [19]
LZF13 AAT YECDHCGKAFSVSSNLNVHRRIH Bae et al., 2003 [19]
LZF14 GTD, GCD YTCKQCGKAFSVSSSLRRHETTH Bae et al., 2003 [19]
LZF15 GCW YECNYCGKTFSVSSTLIRHQRIH Bae et al., 2003 [19]
LZF16 GTG FACPECPKRFMRSDALTRHIKTH Liu et al., 2002 [18]
LZF17 GGC FMCTWSYCGKRFTDRSHLARHKRTH Liu et al., 2002 [18]
LZF18 GCC FACPECPKRFMDRSDLTRHIKTH Liu et al., 2002 [18]
LZF19 AAG FACPECPKRFMRSDNLTQHIKTH Liu et al., 2002 [18]
LZF20 RTC YSCGICGKSFSDSSAKRRHCILH Bae et al., 2003 [19]
LZF21 GRA, MGA YVCRECGRGFRQHSHLVRHKRTH Bae et al., 2003 [19]
LZF22 MAA YMCSECGRGFSQKSNLIIHQRTH Bae et al., 2003 [19]
LZF23 VGA, GAA YECHDCGKSFRQSTHLTRHRRIH Bae et al., 2003 [19]
LZF24 GGW YRCEECGKAFRWPSNLTRHKRIH Bae et al., 2003 [19]
LZF25 NNN YACPVESCDRRFSRKWLLRLHIRIH Joung et al., 2000 [17]
The full amino acid sequence of each finger and the expected target subsite(s) bound by each finger are shown.
doi:10.1371/journal.pone.0021112.t001
Figure 1. Schematic representation of ZF-TF combinatorial library screening approach. (A) Four-ZF-TF protein and mode of DNA target
site recognition. Each finger recognizes 3-bp, and the four-ZF-TF can potentially recognize a 12-bp target. (B) Construction of randomized
combinatorial ZF-TF library. Twenty five DNA fragments each encoding a different ZF (colored spheres) are randomly ‘‘mixed and matched’’ to create
compound DNA segments that encode different four-finger combinations. The library of compound DNA segments is recombined to plasmid which
generates a library of artificial ZF_TF transcription factors in which the combinatorial zinc finger arrays are fused to the NF-KB p65 transcriptional
activation domain. (C) Drug resistance screening design. Retrovirions encoding the ZF-TF library are used to transduce MCF7-R73 cells. Each
transduced MCF7-R73 cell expresses a different ZF-TF that alters the expression of various target genes leading to phenotypic variation. Stably
transduced cells are selected for fulvestrant resistance, ZF-TFs conferring resistance are rescued by PCR, DNA encoding clonal ZF arrays are re-cloned
into a retroviral plasmid, retrovirus is produced, and MCF7-R73 cells transduced by retrovirus bearing individual ZF-TFs. (D) ZF-TF fulvestrant-resistant
cell colonies. MCF7-R73 cells were transduced with control or ZF-TF retrovirions, and exposed to 100 nM fulvestrant. Six weeks post-retroviral
transduction, surviving cells were fixed and stained with crystal violet.
doi:10.1371/journal.pone.0021112.g001
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cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in
fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for
21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments. (B and C) Growth curves of MCF7 and
T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n=8; time in days as indicated)
of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the
presence (blue line) or absence (pink line) of fulvestrant. (D) Drug sensitivity of fulvestrant non-selected MCF7 ZF-TF cells. MCF7 cells transduced with
one of six different ZF-TF-expressing retroviruses and selected in puromycin for 1 month were grown in the absence of fulvestrant for 7 days and
then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. (E) Drug sensitivity
of MCF cells transduced with ZF-TFs lacking the NF-KB p65 activation domain. MCF7 cells infected with retroviruses encoding ZF-TFs (7,19, 64, 70, 83
and 115) lacking the NF-KB p65 activation domain were selected in puromycin for 1 month and then challenged with 100 nM fulvestrant or vehicle
(0.1% ethanol) for 21 days followed by crystal violet staining for visualization.
doi:10.1371/journal.pone.0021112.g002
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previously identified by another group [19]. These fulvestrant-
resistant clones isolated by Coser et al. represent rare, pre-existing
cells from the heterogeneous mixture of cells found in the MCF7
cell line [19]. Several of the gene clusters (clusters 1, 3 and 4) that
were up-regulated by the ZF-TFs were also selectively up-
regulated in some of the naturally selected pre-existing fulvestrant
resistant cells [19] (Figure 3 B, black and purple rectangles). ZF-
TF 64 was associated with a unique set of upregulated genes
(cluster 2), not observed by Coser et al. in any of their previously
published fulvestrant-resistant clones. However, the common
fulvestrant-resistant gene expression signature (cluster 5) was also
observed in the fulvestrant-resistant cells identified by Coser et al.
(Fig. 3B, green rectangle). Thus, taken together, these results
confirm previous findings by Coser et al. and, also provide
evidence for the existence of alternative molecular pathways
associated with fulvestrant resistance.
To determine the potential clinical relevance of our approach,
we assessed whether the common fulvestrant-resistant gene
expression signature (cluster 5) might have prognostic value for
patients with breast cancer. We hypothesized that a drug
resistance phenotype would be associated with a more aggressive
clinical course and thus its gene expression signature would
correlate with poor prognosis. To test this hypothesis, we formed a
‘‘fulvestrant-resistant metagene’’ signature by averaging the
expression of the 72 genes (cluster 5) that constitute the common
fulvestrant resistance gene expression signature, and tested this
metagene in five independent previously published human breast
cancer data sets by Wang et al. (286 patients) [28], van de Vijver et
al. (295 patients) [29], Chin et al. (130 patients) [30], Miller et al.
(251 patients) [31] and Sotiriou et al. (189 patients) [32]. In four of
five data sets, fulvestrant resistant-metagene values (i.e. tumors that
express the fulvestrant resistance gene expression signature)
correlated with poor prognosis, significantly so in two of the data
sets (Figure 4). These clinical correlation data support the notion
that our ZF-TF-based approach can be used to develop
biomarkers with potential clinical relevance.
Discussion
Previous advances in the clinical treatment of breast cancer
have been strongly influenced by data from in vitro-based
approaches in which drug-resistant cells emerge under selective
drug pressure [33,34,35]. In this study, we undertook a different
approach in which we identified six members of a combinatorial
zinc finger transcription factor library capable of inducing stable
anti-endocrine drug resistance in a clonal breast cancer cell line.
Our results stand in contrast to other recent studies in which in
vitro-based drug resistance in breast cancer cells have arisen by the
selection of pre-existing drug-resistant progenitor cells [19].
Differential gene expression analysis identified a common set of
Table 2. Composition of Zinc Finger-Transcription Factor
Arrays Conferring Fulvestrant Resistance.
ZF-TF clone # Finger 1 Finger 2 Finger 3 Finger 4
7 LZF15 LZF23 LZF10 LZF20
19 LZF10 LZF02 LZF18 LZF12
64 LZF08 LZF25 LZF11 LZF23
70 LZF12 LZF03 LZF04 LZF21
83 LZF10 LZF25 LZF19 LZF23
115 LZF13 LZF14 LZF13 LZF23
Full details and sequences of the individual fingers shown for each ZF-TF are
provided in Table 1.
doi:10.1371/journal.pone.0021112.t002
Figure 3. Clustering of expression profiles from ZF-TF-induced fulvestrant resistant cells. (A) MCF7 cells transduced with ZF-TF-encoding
retrovirus or a control virus. Green box identifies a cluster of 72 genes that are consistently down-regulated by ZF-TF expression- these genes
constitute the common fulvestrant-resistant gene expression signature. Black and purple boxes illustrate that gene clusters that are up-regulatedb y
subsets of the six different ZF-TFs. Data represent gene expression profiles from replicate retroviral infections and microarray hybridizations. (B) Pre-
existing fulvestrant resistant clones and control MCF-7 cells from Coser et al [19]. Genes are arranged in the same order as in (A). Green box shows
that genes down-regulated by all the ZF-TF infections were also down-regulated in the pre-existing fulvestrant resistant sub-population. Black and
purple boxes show that some of the gene clusters that were up-regulated by various ZF-TFs were also up-regulated in either two or three (F40-6-V,
F40-7-V and F100-16-V) of the four previously described pre-existing fulvestrant resistant subpopulations in the MCF7 cell line [19].
doi:10.1371/journal.pone.0021112.g003
Transcription Factor Induced Drug Resistance
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Because our ZF-TFs are expected to be activators of gene
expression, we hypothesize that repression of these common genes
is indirect, presumably through activation of one or more
transcriptional repressor proteins.
Interestingly, gene set enrichment analysis of the common
fulvestrant resistance gene expression signature (cluster 5)
revealed that it is composed of genes whose expression is
modulated by estradiol [27,36,37,38]. Because all of these genes
were decreased in their expression, the ZF-TF-induced fulves-
trant resistance we observed is likely to be associated with the
generation of an ‘‘estrogen receptor-negative’’ cell state. These
findings are consistent with that of Creighton et al. in which
tamoxifen-resistant and fulvestrant resistant MCF7-HER2-over-
expressing xenografts shut down classic estrogen receptor gene
expression signaling pathways [26]. Together these observations
are reminiscent of the clinical setting in which anti-estrogen
resistant human breast cancers behave in an aggressive estrogen-
independent manner [14]. In addition, our GSEA results
confirmed the relevance our ZF-TF approach, as our common
fulvestrant resistance gene expression signature demonstrated
highly significant overlap with multiple previously described
breast cancer anti-hormonal resistance gene sets. Specifically our
signature demonstrated significant overlap with those observed
for tamoxifen, fulvestrant and aromatase inhibitor resistance in
multiple breast cancer cell lines including long term estrogen
deprived (LTED) cells [24,25,26,27] . Whether any single genes
or subset of genes within these overlapping gene sets serves as a
‘‘passenger’’ or ‘‘driver’’ of anti-hormonal resistance remains to
be determined.
In addition, our gene set enrichment analysis also identified
four unique myb-regulated gene sets in the ZF-TF-induced
fulvestrant resistant cells. Intriguingly, c-myb is expressed in a
high proportion of ER-positive breast cancers [39] and plays a
pro-proliferative role in ER-positive, but not ER-negative breast
cancer [40]. Expression of c-myb is regulated by estrogen and
antiestrogens, and is altered in long-term estrogen deprived
(LTED) breast cancer cell line model of estrogen-independent
growth [41]. Our analyses identified four unique and indepen-
dent myb-regulated gene sets, rather than a single overlapping
set, a result similar to that observed by Lei et al. [23]. More
specifically, expression of myb proteins in different cell types
resulted in the activation of unique and nearly non-overlapping
sets of genes in each cellular context. Furthermore, deletion and
domain swap experiments resulted in the identification of unique
positive and negative elements in myb that regulate different
cassettes of gene expression [23]. Thus, we hypothesize that the
mostly non-overlapping sets of myb-regulated genes are up-
regulated by the different ZF-TFs in various contexts. Further-
more, taken together, our data suggest that c-myb’s potential role
in anti-estrogen resistance extends beyond the mere expression of
c-myb itself and is likely influenced by other as yet to be defined
factors, which may serve as interesting avenues for future
research.
Figure 4. Prediction of breast cancer outcome using a fulvestrant-resistant gene signature identified by our ZF-TF-based approach.
Patients were stratified using a metagene that was formed by averaging the expression of the 72 genes constituting the common signature for the
fulvestrant resistance phenotype (i.e., the genes of cluster 5 in Fig. 3A). Tumors with metagene values below the median were defined as the
‘‘fulvestrant-resistant metagene’’ and the others as the ‘‘fulvestrant-sensitive metagene.’’ Kaplan-Meier curves for distant metastasis-free survival or
death-from-relapse-free survival using the metagene are based on clinical data described by (A) Wang et al., N=286 [28], (B) van de Vijver et al.,
N=295 [29], (C) Chin et al., N=130 [30], (D) Miller et al., N=251 [31] and (E) Sotiriou et al., N=189 [32]. p-values are one-sided.
doi:10.1371/journal.pone.0021112.g004
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ZF-TF library screening can be used to identify genes associated
with specific phenotypes of interest. One of the strengths of the
ZF-TF approach is that each member of the library has the
potential to regulate the expression of dozens to hundreds of genes
in a cell. This promiscuity, seen in our gene expression analysis, is
not unexpected given the frequency with which any 9 to 12 bp site
(the length of DNA that will likely be bound by a four-finger
protein) will occur just by chance in random sequence and stands
in contrast to other RNAi or cDNA overexpression libraries where
individual members of the library are expected to be specific in
their effects. We speculate that this ability of a single ZF-TF to
regulate multiple genes might provide an advantage for inducing
complex phenotypes that may require the alteration of multiple
cellular pathways. Earlier studies have suggested that differential
gene expression analysis of multiple ZF-TFs can help to define
genes with altered expression associated with an induced
phenotype [7]. Our study includes the largest number of ZF-TFs
that have been profiled for a single induced phenotype and lend
important additional support to the concept that genes responsible
for phenotypes can be deduced despite the relative promiscuity of
the individual ZF-TFs.
Although the combinatorial ZF-TF library we constructed for
this report consists of zinc finger arrays linked to a transcriptional
activation domain, additional libraries consisting of fusions to
other functional domains could also be easily constructed. Building
of such libraries can be easily performed because our library is
encoded on a plasmid in which the coding sequences of the zinc
fingers are flanked by Gateway recombination sites. As we did for
the experiments of this study, the zinc finger library coding
sequences can therefore be readily transferred to any appropriate
Gateway Destination vector and could be easily fused to various
other functional domains (e.g.—transcriptional repression do-
mains, histone modification domains, or DNA methyltransferases).
We also note that the Gateway cloning sites in our library vectors
greatly simplified rescue of zinc finger coding sequences from
genomic DNA of drug-resistant cells and subsequent regeneration
of viral vectors.
In summary, our results provide another important proof-of-
principle for the use of combinatorial ZF-TF libraries to induce
and to study important cellular phenotypes. The features of our
combinatorial library should facilitate construction of additional
ZF fusion protein libraries and simplify the rescue of ZF fusions
from cells exhibiting the desired phenotype. Because members of
the combinatorial library are predicted to have diverse effects on a
cell and because zinc fingers are known to bind DNA in cell types
ranging from humans to bacteria, we envision that this broadly
applicable tool will play an important role in functional genomics
and bioengineering for a wide variety of different organisms. The
results from this study underscore the clinical relevance of our
approach and serve as a relevant model for studying cancer drug
resistance.
Materials and Methods
Cell Culture and Reagents
MCF7-R73 cells, a clonal isolate derived from the MCF7 cell
line were kindly provided by Dr. Toshi Shioda (MGH, Charles-
town, MA) and maintained in a xenoestrogen controlled
environment as described [19], and the T47D and 293T cells
were obtained from American Type Culture Collection (Manassas,
VA) and maintained as described. Fulvestrant was purchased from
Selleck Chemicals LLC (Houston, TX). Puromycin was purchased
from Sigma-Aldrich (St.Louis, MO).
ZF-TF Retroviral Library Production and Drug Resistance
Screening
293T cells were seeded at 5610
5 cells per 10 cm culture dish,
transfected with 3.2 micrograms of ZT-TF p65 activator library
DNA and 2.4 micrograms and 0.8 micrograms of PMD-MLV
and PMD-G plasmid DNA using Fugene 6 (Roche Applied
Science, Indianapolis IN) according to the manufacture’s protocol
and retroviral supernatant harvested 48 hrs later. MCF7-R73 cells
(6610
5 per 10 cm plate) were infected with 1.33610
5 ZF-TF
retrovirions in media containing polybrene. Two days post-
infection the cells were exposed to puromycin (0.4 mg/ml), and
three days later were subjected to continuous combined puromy-
cin and fulvestrant (100 nM) selection for an additional 42 days.
Retroviral DNA was recovered by PCR, subcloned into the
pDONOR plasmid using Gateway technology (Invitrogen), and
subject to DNA sequencing that revealed 46 unique ZF-TF arrays.
The 46 ZF-TFs were re-cloned into the retroviral destination
plasmid using Gateway technology, 46 ZF-TF retroviral superna-
tants generated, and MCF-R73 cells infected and subjected to
puromycin and fulvestrant selection. Six unique ZF-TFs conferred
drug resistance in the presence of continuous fulvestrant exposure.
A control MCF7 cell line (MCF7-R238) was generated by
infecting MCF7-R73 cells with a retrovirus bearing the p65
activation domain only. T47D cells were infected with the six
unique ZF-TF bearing retroviruses and subjected to fulvestrant
exposure as described for the MCF7 cells.
Growth Assays and Crystal Violet Staining
ZF-TF infected MCF7 and T47D cells, and corresponding
control cells were seeded at 1 or 2610
3 cells per 96-well plate and
grown at 37uC in a humidified incubator containing 5% CO2 in the
presence of puromycin (0.4 micrograms/ml) only and puromycin
plus 100 nM fulvestrant for 10–15 days. At the designated time
points, cells were washed by PBS, fixed with 4% formaldehyde in
PBS for 20 minutes, washed four times with distilled water, and
stained with the Syto 60 (Invitrogen) nuclear stain for 45 minutes in
a dark room. Syto 60 staining was measured with an Odyssey (LI-
COR) 96-well plate reader, and values normalized as % control at 0
day point in puromycin (0.4 micrograms/ml) only treated cells and
puromycin plus 100 nM fulvestrant treated cells. The results were
expressed as means + standard errors for 8 replicate determinations
for each experiment. For crystal violet staining assays 1610
5 cells
were seeded in each well of 6 well plate, treated with puromycin
(0.4 micrograms/ml) only or puromycin in combination with
100 nM fulvestrant for 3 weeks (or no fulvestrant was treated for 3
weeks, washed in PBS, fixed with 4% formaldehyde in PBS, and
stained with 0.2% crystal violet in 10% ethanol. Stained cells were
washed multiple times with distilled water, dried and images
captured.
Gene Expression Profiling
Transcriptional profiling was performed using Affymetrix
U133-plus 2.0 microarrays as previously described [42]. Control
and ZF-TF-infected MCF7 cells were profiled from two
independent infections and the profiling was performed in four
batches. The MAS5 algorithm was used to produce non-log-
transformed expression values such that the 2% trimmed mean of
the expression values for each sample was 100. The expression
values were corrected for batch effect on a per-probe-set basis as
follows. For each batch N other than the first, we added to the
expression values of batch N the difference between the average
expression value on the first batch and the average expression
value on batch N. All microarray data are MIAME compliant and
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Omnibus and are accessible [GEO: GSE27444].
Clustering Analysis
The probe-sets with the top 2,500 standard deviations in
expression value were retained and the others discarded. The
resulting matrix was median polished and then each row was scaled
to have mean 0 and standard deviation 1. The resulting matrix was
clustered using average-linkage agglomerative hierarchical cluster-
ing with distance given by one minus the correlation coefficient.
From the pre-existing fulvestrant resistant sub-population and
control data the same 2,500 probe-sets were retained and the rest
discarded. The resulting matrix was median polished and then each
row was scaled to have mean 0 and standard deviation 1.
Hypergeometric Gene Set Enrichment Analysis
A gene-set database was formed by augmenting version 3.0 of the
Broad Institute’s MSigDB gene set database [21] with the six gene
sets found by Wirapati, et. al. [22], to be either correlated or anti-
correlated with ESR1, ERBB2 and AURKA, and with the myb-
regulated genes defined in the supplementary data of Lei
et al. [23] and with the 99 gene LTED signature defined in
supplementary table S4 of Miller et al. [24]. For each gene cluster in
Fig. 3A, we did the following. For each gene-set in the gene-set data
base, a hypergeometric test was performed to determine whether
the intersection of the gene-set with the genes in the gene cluster in
Fig.3A was largerthan would be expected by chancehad both been
drawn at random from all the genes on the Affymetrix U133-plus
2.0 microarray. The resulting p-values were adjusted by the Holm
method to control family-wise error rate (FWER).
Kaplan-Meier Analysis
A metagene was formed by averaging the expression of the 72
genes that constituted a common signature for the fulvestrant
resistance phenotype (i.e., the genes of cluster 5 in Fig. 3A).
Tumors with metagene values below the median were defined to
be ‘‘fulvestrant- resistant’’ and the others ‘‘fulvestrant sensitive.’’
Log-rank test was used to test the hypothesis that fulvestrant-
resistant metagene tumors would have worse survival than
fulvestrant-sensitive metagene tumors. If distant metastasis-free
survival data was available for a particular data set, it was utilized;
otherwise death-from-relapse-free survival data was used. P-values
are one-sided.
Supporting Information
Figure S1 Expression of ER2alpha in the ZF-TF-trans-
duced fulvestrant resistant cells. Control-transduced (R238)
and ZF-TF transduced fulvestrant resistant cells (F7, 19, 64, 70, 83
and 115) were exposed to vehicle or fulvestrant (100 nM) for 6 days.
Cells were lysed in RIPA buffer containing protease inhibitor, and
100 micrograms of each lysate was loaded onto a 10% SDS-PAGE
gel and subjected to Western blotting as previously described [43]
using ER-alpha and beta-actin antibodies (Santa Cruz).
(TIF)
Figure S2 Drug Sensitivity of ZF-TF-transduced fulves-
trant resistant cells. Control MCF7 (R238 cells) and ZF-TF
fulvestrant resistant (F7, 19, 64, 70, 83 and 115) cells (56103) were
exposed to vehicle or 20 uM of multiple selective target inhibitors
(see supplemental Table 1) for 72 hrs as previously described. Cell
growth/viability was quantitated by fluorescent nucleic acid
staining of fixed cells using Syto60 (Molecular probes) and a
SpectraMax M5 plate reader. Each bar represents signal intensity
of the treated cells relative to the non-treated cells, and drug
sensitivity is calculated as the fraction of viable treated-cells
relative to untreated-cells within each cell type. A single and
double asterisk represents significant (p,0.05) drug sensitivity in
which the value of signal intensity of treated cells relative to that of
non-treated cells is 0.5–0.75 and 0.2–0.5, respectively; pink-
colored bar represents similar drug sensitivity pattern to the
parental cell line, R73. The frequency of values falling in each
group from different cell lines were tested against the frequency of
values expected in each group from the same cell lines by Chi
Square analysis; differences in drug sensitivity between the control
cells (R73) and the ZF-TF transduced cells (F11, F19 and F64)
were not statistically significant.
(TIF)
Table S1 Chemotherapeutic agents and investigational
compounds used in the drug sensitivity screen.
(XLS)
Table S2 Genes (72) constituting the common fulves-
trant-resistant gene expression signature.
(XLS)
Table S3 Gene Sets enriched in ZF-TF 7, 19, and 70-
induced fulvestrant resistant cells (Gene Cluster 1: 230
genes).
(XLS)
Table S4 Gene Sets enriched in ZF-TF 64-induced
fulvestrant resistant cells (Gene Cluster 2: 225 genes).
(XLS)
Table S5 Gene Sets enriched in ZF-TF 83-induced
fulvestrant resistant cells (Gene Cluster 3: 135 genes).
(XLS)
Table S6 Gene Sets enriched in ZF-TF 115-induced
fulvestrant resistant cells (Gene Cluster 4: 123 genes).
(XLS)
Table S7 Gene Sets enriched in all ZF-TF-induced
fulvestrant resistant cells (Gene Cluster 5: 72 genes).
(XLS)
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